$111.56
-1.33-1.18%
At close: Sep 29, 5:00 PM EST
$111.56
N/A
After Hours: 4:01 PM EST
Halozyme Therapeutics Inc
HALONASDAQ
Halozyme Therapeutics Earnings & Forecasts
Halozyme Therapeutics (HALO) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Halozyme Therapeutics Guidance
Halozyme Therapeutics (HALO) last issued guidance on August 6, 2026 for fiscal year 2026. The company guided earnings per share in the range of $8.65 - $9, compared to a consensus EPS estimate of $8.02. Halozyme Therapeutics also guided revenue in the range of $1.83B - $1.91B for the period.
Compared to prior guidance, Halozyme Therapeutics raised its EPS outlook from a previous range of $7.75 - $8.25. On the revenue side, the company raised its revenue forecast from a prior range of $1.71B - $1.81B.
Halozyme Therapeutics has issued 25 guidance updates between November 8, 2022 and August 6, 2026. During this period, the company raised its outlook 14 times, reflecting management's growing confidence in business performance.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.80 | $1.51 | $2.15 | $1.58 |
| Actual | $2.28 | $1.60 | $-0.24 | $1.72 |
| Surprise | +26.7% | +5.96% | -111.2% | +8.86% |
| Revenue | ||||
| Estimate | $405.2M | $358.8M | $447.1M | $338.3M |
| Actual | $481.0M | $376.7M | $451.8M | $354.3M |
| Surprise | +18.7% | +4.99% | +1.04% | +4.72% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $2.26 | $2.57 | $1.78 | $2.04 |
| Revenue | ||||
| Consensus | $481.6M | $538.4M | — | — |
